BioMed Research International / 2019 / Article / Tab 1

Clinical Study

A Nomogram Predicting Microvascular Invasion Risk in BCLC 0/A Hepatocellular Carcinoma after Curative Resection

Table 1

Patient characteristics.

VariableTraining group (n=60)Validation group (n=29)T/P value

Age, y51.7±12.757.8±10.7-2.2380.028
Gender (male, female)50/1026/30.2220.637
BMI, Kg/m222.7±3.723.2±2.5-0.6490.518
PLT,/L195.9±142.6138.1±79.32.0310.045
ALB, g/L40.7±6.040.0±4.20.6600.511
TB, umol/L18.0±22.113.6±14.90.9570.341
ALT, U/L60.0±77.147.4±43.40.8160.417
AST, U/L64.2±97.240.7±30.01.2700.208
GGT, U/L107.8±193.588.7±95.50.5020.617
PT, S13.7±1.013.7±1.0-0.0530.958
PTA, %93.6±12.890.5±12.01.0900.279
Liver Function Grading (A/B)58/228/1- - -1.000
HBV DNA(<10e3, ≥ 10e3IU/mL)46/1419/101.2340.267
AFP(≤400,>400ng/ml)45/1522/70.0080.930
HCV (Absent, Present)59/128/1- - -0.548
Tumor size, cm6.0±3.95.0±3.71.0920.278
CT value in unenhanced phase (≤42.5,>42.5)28/326/235.5880.018
CT value in artery phase(≤66.5,>66.5)20/409/200.0470.828
CT value in venous phase(≤102,>102)44/1620/90.1850.667
CT value in delayed phase(≤103.5,>103.5)51/924/50.0020.970
Located in the left lobe (Absent, Present)44/1620/90.1850.667
Capsule (Absent, Present)44/1625/41.8600.173
With smooth margin (Absent, Present)51/918/115.9010.015
Peritumoral enhancement (Absent, Present)47/1324/50.2370.626
Visible small blood vessel (Absent, Present)21/3915/142.2700.132
The distance from the IVC3.2±2.34.2±2.6-1.5400.127
The distance from the portal vein branches3.6±2.35.0±2.5-1.7700.080
Liver cirrhosis (Absent, Present)35/2516/130.0800.778
MVI (Absent, Present)32/2816/130.0270.870

Abbreviations: BMI: body mass index; PLT: platelet; ALB: albumin; TB: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase; PT: prothrombin time; PTA: prothrombin activity; HBV: hepatitis B virus; AFP: alpha fetoprotein; HCV: hepatitis C virus; MVI: microvascular invasion.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.